Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexuprazan in patients with NERD
NCT06121830Phase 3Recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Aug 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fexuprazan in Non-erosive Gastroesophageal Reflux Disease (NERD), sponsored by Daewoong Pharmaceutical. Started Aug 2023; status: recruiting.
02
Drugs
fexuprazan
03
Conditions
Non-erosive Gastroesophageal Reflux Disease (NERD)
Beyond the preview
Go deeper on NCT06121830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06121830.